Retrophin Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Retrophin (RTRX) PT Trimmed to $44 at Leerink Partners Post Q3, 'Outperform' Maintained
November 4, 2015 6:54 AM ESTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating but lowered his price target on Retrophin (NASDAQ: RTRX) to $44.00 (from $48.00) following Q3 results which beat on the top line. They note patient indemnification efforts are in focus.
Schwartz commented, "RTRX reported 3Q... More



